{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:38:25Z","timestamp":1791578305488,"version":"4.3.4"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyrotropin-binding inhibitory immunoglobulin (TBII) is involved in the pathogenesis of Graves\u2019 orbitopathy (GO). Although thyroid-stimulating immunoglobulin (TSI) may offer superior diagnostic or prognostic value, its utility remains incompletely defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 177 consecutive patients with GO, comprising 128 newly diagnosed cases and 49 individuals with a history of intravenous methylprednisolone (IVMP) therapy. All participants underwent standardized evaluations, including endocrine assessments, ophthalmic examinations, and orbital magnetic resonance imaging (MRI). MRI was used to quantify the maximum signal intensity ratio of the extraocular muscles (SIR max) and the volume of the extraocular muscles (EMV). TBII levels were measured using a third-generation competitive-binding immunoassay, and TSI levels were assessed using a bridge-based chemiluminescence immunoassay. Treatment response to combined IVMP and mycophenolate mofetil (MMF) was evaluated in a subgroup of 70 newly diagnosed patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In newly diagnosed patients, the TSI positivity rate was significantly higher than that of TBII (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Notably, only within this subgroup did both antibodies show a positive correlation with the clinical activity score (CAS) (TBII: r=0.354,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001, TSI: r=0.323,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) and SIR max (TBII: r=0.234,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.008; TSI: r=0.175,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.048). Multivariate analysis identified age (\u03b2=0.297,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002), TBII (\u03b2=0.365,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), and TSI (\u03b2=0.325,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.003) as independent factors associated with CAS. An age-stratified analysis demonstrated stronger correlations between antibody levels and CAS in patients older than 45 years (TBII-CAS: r=0.410; TSI-CAS: r=0.426), with correspondingly higher areas under the curve (AUC) for identifying active disease (TBII: 0.736; TSI: 0.760). In evaluating treatment response to IVMP combined with MMF, higher baseline TSI levels (OR = 1.086, 95% CI: 1.014\u20131.163), elevated SIR max (OR = 9.205, 95% CI: 1.072\u201379.053), and lower HDL levels (OR = 0.033, 95% CI: 0.003\u20130.346) were independently associated with poor outcomes. In contrast, TBII did not retain independent predictive value in this treatment context.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In newly diagnosed patients with GO, both TBII and TSI levels were associated with disease activity, with their diagnostic value being more pronounced in older individuals. TSI demonstrated a higher positivity rate than TBII and served as an independent predictor of treatment response to IVMP combined with MMF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1657160","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:56:07Z","timestamp":1765886167000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Age-dependent diagnostic and treatment response prediction of TBII and TSI in Graves\u2019 orbitopathy: integration with orbital MRI biomarkers"],"prefix":"10.3389","volume":"16","author":[{"given":"Cheng","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qintao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genfeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanping","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbo","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/jcm10010016","article-title":"Current knowledge on graves\u2019 Orbitopathy","volume":"10","author":"Gontarz-Nowak","year":"2020","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1998.8.193","article-title":"Thyrotropin receptor expression in cultured Graves\u2019 orbital preadipocyte fibroblasts is stimulated by thyrotropin","volume":"8","author":"Bahn","year":"1998","journal-title":"Thyroid"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01708.x","article-title":"TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves\u2019 ophthalmopathy patients","volume":"58","author":"Wakelkamp","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves orbitopathy","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2013.54.4.1033","article-title":"Correlation between TSH receptor antibody assays and clinical manifestations of Graves\u2019 orbitopathy","volume":"54","author":"Jang","year":"2013","journal-title":"Yonsei Med J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4309","article-title":"Clinical utility of TSH receptor antibodies","volume":"98","author":"Barbesino","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-016-0478-9","article-title":"Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies","volume":"39","author":"Diana","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1515\/cclm-2016-0197","article-title":"Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves\u2019 disease","volume":"55","author":"Tozzoli","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/00365513.2019.1658216","article-title":"Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin, the Immulite TSI assay","volume":"79","author":"Kim","year":"2019","journal-title":"Scandinav J Clin Lab Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1055\/a-0914-0535","article-title":"Comparison of a bridge immunoassay with two bioassays for thyrotropin receptor antibody detection and differentiation","volume":"51","author":"Allelein","year":"2019","journal-title":"Hormone Metab Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02085-5","article-title":"The phenotype of Graves\u2019 orbitopathy is associated with thyrotropin receptor antibody levels","volume":"46","author":"Sari\u0107 Matutinovi\u0107","year":"2023","journal-title":". J Endocrinol Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1055\/a-2021-0596","article-title":"Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in the management of graves\u2019 Orbitopathy","volume":"131","author":"Khamisi","year":"2023","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-021-02052-0","article-title":"Diagnostic accuracy of Immulite\u00ae TSI immunoassay for thyroid-associated orbitopathy in patients with recently diagnosed Graves\u2019 hyperthyroidism","volume":"42","author":"Thia","year":"2021","journal-title":"Int Ophthalmol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01652-y","article-title":"Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves\u2019 orbitopathy","volume":"45","author":"Sari\u0107 Matutinovi\u0107","year":"2021","journal-title":"J Endocrinologic Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06496-9","article-title":"Peripheral CD3(+)CD4(+) T cells as indicators of disease activity in thyroid eye disease: age-dependent significance","volume":"262","author":"Zhang","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1434155","article-title":"Age and gender influence on clinical manifestations of thyroid-associated ophthalmopathy: a case series of 2479 Chinese patients","volume":"15","author":"Yang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13855","article-title":"Factors associated with the efficacy of intravenous methylprednisolone in moderate-to-severe and active thyroid-associated ophthalmopathy: A single-centre retrospective study","volume":"90","author":"Hu","year":"2018","journal-title":"Clin Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1153312","article-title":"Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves\u2019 orbitopathy","volume":"14","author":"Park","year":"2023","journal-title":"Front Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e177","article-title":"Intravenous glucocorticoid treatment for korean graves\u2019 Ophthalmopathy patients","volume":"35","author":"Ahn","year":"2020","journal-title":"J Korean Med Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1469179","article-title":"Clinical performance of a novel and rapid bioassay for detection of thyroid-stimulating immunoglobulins in Graves\u2019 orbitopathy patients: a comparison with two commonly used immunoassays","volume":"15","author":"H\u00f6tte","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1079628","article-title":"Factors related to steroid treatment responsiveness in thyroid eye disease patients and application of SHAP for feature analysis with XGBoost","volume":"14","author":"Park","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305649","article-title":"Thyroid eye disease: a Southeast Asian experience","volume":"99","author":"Lim","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2024-325346","article-title":"Low clinical activity score, \u2018progressive\u2019 thyroid eye disease: presentations of 1439 patients from a tertiary centre in Hong Kong","volume":"109","author":"Lai","year":"2025","journal-title":"Br J Ophthalmol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.28642","article-title":"Application of multiparameter quantitative magnetic resonance imaging in the evaluation of graves\u2019 Ophthalmopathy","volume":"58","author":"Li","year":"2023","journal-title":"J Magn Reson Imaging"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0304-z","article-title":"T2-relaxation mapping and fat fraction assessment to objectively quantify clinical activity in thyroid eye disease: an initial feasibility study","volume":"33","author":"Das","year":"2019","journal-title":"Eye (Lond)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/eje-14-1140","article-title":"Some studies on the natural history of Graves\u2019 orbitopathy: increase in orbital fat is a rather late phenomenon","volume":"173","author":"Potgieser","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13564","article-title":"Establishment of magnetic resonance imaging 3D reconstruction technology of orbital soft tissue and its preliminary application in patients with thyroid-associated ophthalmopathy","volume":"88","author":"Shen","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12886-023-03008-x","article-title":"Magnetic resonance imaging parameters on lacrimal gland in thyroid eye disease: a systematic review and meta-analysis","volume":"23","author":"Wong","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2013.193","article-title":"Diagnosis and management of Graves disease: a global overview","volume":"9","author":"Bartalena","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09848-x","article-title":"Extraocular muscle volume index at the orbital apex with optic neuritis: a combined parameter for diagnosis of dysthyroid optic neuropathy","volume":"33","author":"Song","year":"2023","journal-title":"Eur Radiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-014-0365-x","article-title":"Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy","volume":"59","author":"Higashiyama","year":"2015","journal-title":"Jpn J Ophthalmol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02367-5","article-title":"Predicting the response to glucocorticoid therapy in thyroid-associated ophthalmopathy: mobilizing structural MRI-based quantitative measurements of orbital tissues","volume":"70","author":"Hu","year":"2020","journal-title":"Endocrine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","article-title":"Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy","volume":"16","author":"Bahn","year":"1987","journal-title":"Endocrinol Metab Clinics North America"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0280","article-title":"Predictive model for graves\u2019 Ophthalmopathy in patients with new-onset graves\u2019 Disease","volume":"32","author":"Ahn","year":"2022","journal-title":"Thyroid"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fragi.2023.1234572","article-title":"Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration","volume":"4","author":"Thakolwiboon","year":"2023","journal-title":"Front Aging"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/678194","article-title":"Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbitopathy: A prospective study","volume":"2015","author":"Kampmann","year":"2015","journal-title":"Int J Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5603\/ep.98156","article-title":"Differential diagnosis of thyroid orbitopathy \u2014 diseases mimicking the presentation or activity of thyroid orbitopathy","volume":"75","author":"Nowak","year":"2024","journal-title":"Endokrynol Polska"},{"key":"B39","doi-asserted-by":"publisher","first-page":"100101","DOI":"10.1016\/j.apjo.2024.100101","article-title":"Advances in understanding and management of IgG4-related ophthalmic disease","volume":"13","author":"Lai","year":"2024","journal-title":"Asia-Pacific J Ophthalmol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.52.735","article-title":"Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves\u2019 disease","volume":"52","author":"Kubota","year":"2005","journal-title":"Endocr J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13052-021-00999-5","article-title":"Effects of glucocorticoid pulse therapy on thyroid function and thyroid antibodies in children with graves\u2019 disease","volume":"47","author":"Hu","year":"2021","journal-title":"Ital J Pediatr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2024-325180","article-title":"Effect of intravenous methylprednisolone on serum antibody levels in thyroid eye disease","volume":"109","author":"Lee","year":"2025","journal-title":"Br J Ophthalmol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2015.29.4.213","article-title":"Clinical association of thyroid stimulating hormone receptor antibody levels with disease severity in the chronic inactive stage of graves\u2019 Orbitopathy","volume":"29","author":"Woo","year":"2015","journal-title":"Korean J Ophthalmol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ15-0137","article-title":"TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves\u2019 ophthalmopathy in untreated Japanese Graves\u2019 disease patients","volume":"63","author":"Mukasa","year":"2016","journal-title":"Endocr J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2000.10.809","article-title":"Thyroid-stimulating antibody is related to Graves\u2019 ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves\u2019 disease","volume":"10","author":"Noh","year":"2000","journal-title":"Thyroid"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01353-y","article-title":"Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves\u2019 orbitopathy","volume":"44","author":"Nicol\u00ec","year":"2020","journal-title":"J Endocrinologic Invest"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02705","article-title":"High titers of thyrotropin receptor antibodies are associated with orbitopathy in patients with graves disease","volume":"104","author":"Kahaly","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-024-01061-7","article-title":"Correlation between extraocular muscle enlargement and thyroid autoantibodies in thyroid eye disease","volume":"68","author":"Koizumi","year":"2024","journal-title":"Japanese J Ophthalmol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0173","article-title":"A multicenter, single-blind, case-control, immunohistochemical study of orbital tissue in thyroid eye disease","volume":"32","author":"Hai","year":"2022","journal-title":"Thyroid"},{"key":"B50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/iovs.63.12.27","article-title":"Differential circular RNA expression profiling of orbital connective tissue from patients with type I and type II thyroid-associated ophthalmopathy","volume":"63","author":"Ye","year":"2022","journal-title":"Invest Opthalmol Visual Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-12741","article-title":"Orbital fibroblasts from thyroid eye disease patients differ in proliferative and adipogenic responses depending on disease subtype","volume":"54","author":"Kuriyan","year":"2013","journal-title":"Invest Opthalmol Visual Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"107502","DOI":"10.1016\/j.pharmthera.2020.107502","article-title":"TSH\/IGF1 receptor crosstalk: Mechanism and clinical implications","volume":"209","author":"Krieger","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01369","article-title":"\u03b2-arrestin based receptor signaling paradigms: potential therapeutic targets for complex age-related disorders","volume":"9","author":"van Gastel","year":"2018","journal-title":"Front Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733566","article-title":"The dynamics of B cell aging in health and disease","volume":"12","author":"de Mol","year":"2021","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-092419-031130","article-title":"Age-associated B cells","volume":"38","author":"Cancro","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.5.57","article-title":"Elevated immunoglobulin G4 levels in patients with thyroid eye disease and their clinical implications","volume":"61","author":"Ye","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.55563\/clinexprheumatol\/1b9d13","article-title":"Expansion and surface makers of age-associated B cells in IgG4-related disease","volume":"42","author":"Zhang","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1882","article-title":"IL-17A exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO","volume":"101","author":"Fang","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1474-9726.2012.00812.x","article-title":"Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of IL-17 producing T cells","volume":"11","author":"Sun","year":"2012","journal-title":"Aging Cell"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.616949","article-title":"The complex role of regulatory T cells in immunity and aging","volume":"11","author":"Rocamora-Reverte","year":"2020","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1340415","article-title":"Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves\u2019 orbitopathy","volume":"15","author":"H\u00f6tte","year":"2024","journal-title":"Front Endocrinol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.124.320851","article-title":"Interactions between HDL and CD4+ T cells: A novel understanding of HDL anti-inflammatory properties","volume":"44","author":"Atehortua","year":"2024","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00615-2","article-title":"A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves\u2019 orbitopathy","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.648732","article-title":"Mechanisms that underly T cell immunity in graves\u2019 Orbitopathy","volume":"12","author":"Fang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01246-7","article-title":"Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases","volume":"35","author":"Du","year":"2021","journal-title":"Eye (Lond)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1657160\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T14:27:37Z","timestamp":1765895257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1657160\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2025.1657160"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1657160","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"1657160"}}